Medicare Part D Premium Stabilization: What the End of the Demonstration Means for You

The End of the Medicare Part D Premium Stabilization Demonstration

The Medicare Part D Premium Stabilization Demonstration ends in 2027, meaning the temporary cap that kept Part D premiums low will expire and beneficiaries should expect higher, more variable premiums starting with the 2028 plan year. This page explains why the program is ending, who is most exposed, and what steps to take before the change takes effect.

The Medicare Part D Premium Stabilization Demonstration, a temporary federal program quietly shielding roughly 25 million Americans from sharp drug plan cost increases, is drawing to a close. When the Medicare Part D Premium Stabilization Demonstration ends after the 2027 plan year, many beneficiaries relying on stand-alone prescription drug coverage will face a new pricing reality that could hit their monthly budgets harder than anything they have seen in recent years.

Launched in 2024 by the Biden administration, the demonstration was designed with a specific purpose: to prevent sudden, dramatic premium spikes that could follow the Inflation Reduction Act's landmark Part D redesign. The IRA introduced major structural changes to how drug costs are shared between insurers, the government, and beneficiaries. Those changes inadvertently triggered aggressive bidding behavior among plan sponsors, and without intervention, premiums could have jumped significantly all at once.

The stabilization program worked as a buffer, subsidizing plan bids so that insurers would not pass the full cost onto enrollees. Now, with the Trump administration stepping back from this framework, that buffer is disappearing. For the approximately 25 million people enrolled in stand-alone Medicare Part D plans, the end of this demonstration is not a small policy footnote. It is a direct signal that their monthly drug premiums are likely heading upward, and understanding what is coming is the first step toward preparing for it. For a deeper look at how this subsidy program was structured and what its removal means financially, see our detailed breakdown of the Part D subsidy ending in 2027.

Key Facts at a Glance: Understanding the Program and Its Termination

Before examining the downstream effects, it helps to understand the basic architecture of the program itself. Here are the essential facts every beneficiary should know:

1. Created in 2024: The demonstration was established under the Biden administration to stabilize Part D premiums following the sweeping structural changes introduced by the Inflation Reduction Act of 2022.

2. Purpose: It used federal subsidies to offset insurer bids, preventing plan sponsors from passing the full financial burden of the IRA's redesigned cost-sharing structure onto enrollees as sudden premium increases.

3. Cost to taxpayers: The Government Accountability Office (GAO) estimated the two-year cost of the demonstration at approximately $9.8 billion in federal spending.

4. Official end date: The program concludes following the 2027 plan year, meaning no similar stabilization subsidies are expected for 2028 and beyond.

5. 2027 National Base Beneficiary Premium: CMS set the National Base Beneficiary Premium at $41.33 for 2027, which represents a notable increase from 2026 levels.

6. Growth cap mechanics: While the IRA established a 6% annual cap on base beneficiary premium growth, that cap applies only within the demonstration's framework, and its protective effect fades as the program winds down.

7. Scope of impact: Roughly 25 million Americans enrolled in traditional Medicare stand-alone drug plans are directly affected by this policy transition.

The Origin Story: Why the Demonstration Was Created Under the IRA

To understand why the stabilization program existed at all, you need to look back at how Part D worked before the Inflation Reduction Act changed the rules. Prior to 2023, Medicare drug plans operated under a cost-sharing model where beneficiaries faced uncapped out-of-pocket spending. In some cases, people with serious conditions spent thousands of dollars per year on prescriptions before reaching catastrophic coverage thresholds.

The IRA's most celebrated Part D change was a $2,100 annual out-of-pocket cap for beneficiaries (raised from $2,000 in 2025 to $2,100 in 2026), a historic protection for people managing expensive drug regimens. But that cap came with an unintended side effect. By shifting more financial responsibility onto plan sponsors and drug manufacturers, it disrupted how insurers calculated their bids. Insurers suddenly faced significantly higher exposure than before, and many responded by sharply raising their premium bids to compensate.

This bidding behavior alarmed policymakers. If premiums spiked by 20% or 30% overnight, millions of beneficiaries on fixed incomes would face an impossible choice between coverage and other essential expenses. The Biden administration moved quickly to prevent that outcome by launching the stabilization demonstration. By subsidizing a portion of insurer bids directly, the program effectively kept premium growth artificially suppressed through 2026.

The result: average Part D premiums in 2025 and 2026 remained relatively stable even though the underlying structural costs had increased significantly. The demonstration bought time, but it did not resolve the fundamental tension between insurer cost exposure and beneficiary affordability. That tension is now coming to a head as the program ends. You can review the key Part D changes in 2026 to understand how this year's structure compares to what is coming next.

Why the Program Is Ending in 2027: Policy Shifts and Fiscal Realities

The stabilization demonstration's termination is not simply a matter of a program running its natural course. It reflects a deliberate policy decision by the Trump administration to step back from what CMS officials have characterized as an unsustainable federal subsidy model.

Critics within the current administration framed the demonstration as a temporary patch that masked the true cost of the IRA's drug plan redesign. Rather than allowing the market to absorb those costs gradually through transparent premium adjustments, the argument went, the subsidy was shielding insurers from accountability. This placed the bill directly on federal taxpayers, to the tune of nearly $9.8 billion over two years.

MedPAC analysis showed that the subsidies measurably reduced average premiums in both 2025 and 2026 compared to what market bids alone would have produced. That reduction was real and meaningful for beneficiaries, but it came at a fiscal cost that the current administration was unwilling to extend.

CMS announcements in early 2026 made the conclusion clear: the agency would not renew or extend the demonstration beyond the 2027 plan year. The 2027 bid cycle would proceed without the stabilizing subsidies, allowing insurer bids to fully reflect their actual cost exposure under the IRA's revised structure.

For beneficiaries, this shift means that the 2027 plan year represents a genuine inflection point. The 6% annual cap on the National Base Beneficiary Premium offers some protection on paper, but premium increases at the plan level can still move significantly beyond that base figure. The combination of policy retreat and fiscal pressure is now being passed directly to enrollees.

Market Impact: Major Insurers and the 2027 Plan Landscape

The end of the stabilization demonstration is already reshaping how the country's largest Part D plan sponsors are approaching their 2027 bids. UnitedHealth Group, CVS/Aetna, and Humana, the three insurers that collectively cover the majority of Part D enrollees, each face increased cost exposure that they must now price into their premiums without federal support.

CMS 2027 Plan Landscape Release data signals some notable shifts in the market. Several insurers have narrowed their formularies, adjusted cost-sharing structures, or consolidated plan offerings in certain regions. In some states, stand-alone drug plan availability has decreased, meaning beneficiaries may have fewer choices, and the remaining options may carry higher price tags.

State-level variation matters here. Rural states with limited plan competition tend to see less price pressure on insurers, meaning premiums can rise more steeply without beneficiaries having affordable alternatives. Urban markets with multiple competing plans may offer more protection through competitive pricing, but even there, the removal of the subsidy floor pushes bids upward.

For beneficiaries currently enrolled in a stand-alone Part D plan, the 2027 Annual Notice of Change will be a critical document. Reviewing your Annual Notice of Change carefully this fall can help you spot premium or formulary shifts before they take effect. Plan changes that look small in percentage terms can translate to meaningful dollars over a full year, particularly for enrollees managing multiple maintenance medications.

Traditional Medicare vs. Medicare Advantage: The Premium Gap

One of the most consequential effects of the stabilization demonstration ending is how it widens the already visible cost gap between stand-alone Part D plans and the drug coverage embedded in Medicare Advantage plans.

The roughly $28-per-month gap between these two coverage types has existed for years, but as stand-alone Part D premiums climb post-stabilization, that gap is likely to widen further. For a beneficiary comparing options during the Annual Enrollment Period (October 15 - December 7), that difference could amount to over $300 per year in premium savings alone by choosing a Medicare Advantage plan.

However, Medicare Advantage drug coverage is not always a straightforward upgrade. Formulary restrictions, prior authorization requirements, and network limitations can affect whether a specific drug is accessible at a reasonable cost-share. The lower premium does not always mean lower total spending. Understanding Medicare Advantage versus Medicare Supplement differences is essential before making that switch.

What the stabilization demonstration's end does is force more beneficiaries to seriously reconsider whether remaining in traditional Medicare with a stand-alone drug plan remains their best financial option, a calculation that millions will need to work through during the 2026 open enrollment period for 2027 coverage.

Common Mistakes to Avoid

As the Part D landscape shifts heading into 2027, certain missteps can cost beneficiaries significantly. Here are the most common errors to watch out for:

1. Auto-Renewing Your Current Plan Without Reviewing It - Many beneficiaries assume their current plan will stay the same from year to year. With the stabilization program ending, plans that held premiums steady in 2025 and 2026 may look very different in 2027. Read your Annual Notice of Change carefully each fall; do not simply let enrollment roll over automatically.

2. Focusing Only on the Monthly Premium - A lower premium does not always mean lower total drug spending. Deductibles, copays, and formulary tiers all affect your actual cost. In 2026, the maximum Part D deductible is $615. A plan with a $10 lower premium but a higher deductible or worse formulary placement for your drugs can cost you significantly more over the year.

3. Not Checking Whether Your Drugs Are Still Covered - Formularies change annually. Insurers responding to higher cost exposure may shift drugs to higher tiers or remove them from their formulary entirely. Always verify that your specific medications are covered, and at what cost-share level, before selecting or renewing a plan for the coming year.

4. Ignoring Extra Help Eligibility - Millions of eligible beneficiaries never apply for Extra Help (the Low-Income Subsidy), which can dramatically reduce or eliminate Part D premiums and cost-sharing. If your individual income is below approximately $23,475 (2025 threshold), you may qualify. Do not assume you will not be eligible; check before paying full premiums.

5. Assuming Medicare Advantage Drug Coverage Is Always Cheaper - While MAPD plans often show lower drug premiums on paper, switching from traditional Medicare to Medicare Advantage means accepting network restrictions and potential prior authorization hurdles. The switch may not suit your situation if you have complex medical needs or prefer flexibility in choosing specialists.

6. Missing the Open Enrollment Window - The annual open enrollment period (October 15 - December 7) is your primary opportunity to change or switch your Part D plan. Missing this window means you are locked in for the full year. With 2027 premiums likely to shift noticeably, acting during open enrollment is especially important this cycle. Learn more about common enrollment mistakes to avoid.

Who Is Most Exposed to the Part D Policy Change?

Not every Medicare beneficiary will feel the end of the stabilization demonstration equally. The impact falls hardest on specific groups, and understanding where you stand can help you take earlier action.

Beneficiaries enrolled in traditional Medicare with stand-alone prescription drug plans bear the most direct exposure. Unlike Medicare Advantage enrollees, whose drug costs are bundled into a broader plan structure, stand-alone plan enrollees have no offset mechanism. Every dollar increase in the base premium or plan-specific bid hits them directly on their monthly statement.

Low-income beneficiaries who narrowly miss Extra Help eligibility face a particular vulnerability. Those just above the income threshold receive no subsidy protection and must absorb premium increases in full, often on fixed Social Security income. Even modest monthly increases, compounded over time, can strain already tight budgets.

People managing multiple chronic conditions are also at elevated risk. If their medications shift to higher formulary tiers or become subject to increased cost-sharing as insurers tighten their benefit designs, the $2,100 out-of-pocket cap provides some ceiling, but reaching it earlier in the year still causes real financial hardship month-to-month.

Structural barriers compound the problem for some. Beneficiaries currently in traditional Medicare who want to switch to Medicare Advantage for its lower drug premium may find the transition more complex than expected. Medigap switching rules and pre-existing condition underwriting can limit options for those who want to adjust their supplemental coverage simultaneously.

To summarize, the groups facing the highest exposure include:

• Enrollees in traditional Medicare stand-alone prescription drug plans

• Low-income beneficiaries slightly above the Extra Help threshold

• Individuals managing multiple chronic health conditions

Medicare Part D 2028 Premiums and Beyond

As the stabilization demonstration fully concludes, understanding what to expect regarding Medicare Part D 2028 premiums becomes essential for long-term planning. Without the demonstration's federal subsidies, the 2028 plan year will mark the first time since 2023 that insurer bids fully reflect unsubsidized cost exposure under the IRA's restructured Part D framework.

The IRA's 6% annual cap on the National Base Beneficiary Premium provides a nominal guardrail, but individual plan premiums are not bound by this cap. Insurers can and will adjust their specific plan bids based on their formulary costs, membership risk profiles, and competitive positioning. This means some plans could see premium increases well above 6% in a single year, particularly in regions with limited competition.

Market analysts and policy groups, including MedPAC, have flagged that the post-stabilization environment may accelerate plan consolidation. Smaller plan sponsors with less financial flexibility may exit certain markets, reducing choice for beneficiaries and potentially driving premiums higher in those areas.

For beneficiaries planning beyond 2027, the key takeaway is that annual plan comparison during open enrollment is no longer optional. It is a financial necessity. The era of relatively stable, subsidized premiums is ending, and proactive engagement with your coverage options each fall will be the primary tool for managing costs going forward.

💡 Eddie's Pro Tip

Set a calendar reminder for September 15 every year. That is when your Annual Notice of Change arrives, and it gives you a full month to compare plans before open enrollment opens on October 15. Do not wait until December. The beneficiaries who save the most money are the ones who compare their current plan against at least three alternatives using Medicare Plan Finder with their actual drug list entered. Five minutes of comparison can save hundreds of dollars per year.

Action Steps and Available Resources

Regardless of where you fall on the exposure spectrum, there are concrete steps you can take now to prepare for the post-stabilization landscape:

Extra Help (Low-Income Subsidy): The Medicare Extra Help program is worth checking even if you think you are over the threshold; partial assistance may still be available.

Medicare Savings Programs (MSPs): State-administered programs that can help pay Part B premiums and, in some cases, cost-sharing amounts. Qualifying for an MSP may also automatically qualify you for Extra Help on Part D. Learn more about Medicare Savings Programs.

Medicare Prescription Payment Plan: This newer cost-smoothing option lets you spread out-of-pocket drug costs evenly across the year rather than paying large amounts in one month. It does not reduce your total cost but can ease cash-flow pressure during high-cost periods.

SHIP Counseling: State Health Insurance Assistance Programs offer free, unbiased guidance from trained counselors. They can help you compare plans, check formularies, and identify assistance programs you may be eligible for. Contact your state's SHIP before open enrollment closes.

Medicare Plan Finder: Use the official Medicare Plan Finder on Medicare.gov during open enrollment (October 15 - December 7) to enter your specific medications and compare actual estimated annual costs, not just premiums, across available plans in your area. This tool remains the most reliable way to identify your lowest-cost option for 2027.

Frequently Asked Questions